Phase II study of personalized peptide vaccination with both a hepatitis C virus-derived peptide and peptides from tumor-associated antigens for the treatment of HCV-positive advanced hepatocellular carcinoma patients - Yutani, S; Ueshima, K; Abe, K (J Immunol Res, 2015)